Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Novel GnRH antagonists in early development at Takeda

Sep. 29, 2004

Enrollment under way in Modrenal prostate cancer study

Sep. 28, 2004

Alimta approved in Europe for malignant pleural mesothelioma and NSCLC

Sep. 28, 2004

Sopherion licenses North American rights to Myocet

Sep. 28, 2004

New antitumor agents and their use in ALL therapy

Sep. 28, 2004

Pharmion's MAA for Vidaza accepted for review by EMEA

Sep. 27, 2004

Introgen Therapeutics receives NCI grant to further mda-7 gene research

Sep. 27, 2004

New antitumor, antibacterial and antifungal agents isolated from Streptomyces sp.

Sep. 27, 2004

Oxazepine-based antitumor agents newly discovered at Servier

Sep. 27, 2004

Tarceva plus gemcitabine combination improves survival in pancreatic cancer patients

Sep. 23, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...